Physician profile
Michael B Bradshaw
NPI 1861646267
$142,970.84
in general payments reported to CMS, 2019-2025
37 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $10K · 2021: $5,500 · 2022: $6,406 · 2023: $49K · 2024: $26K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Food and Beverage: $8,234 · Travel and Lodging: $6,116 · Consulting Fee: $4,425 · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,450.00 |
| Food and Beverage | $8,234.46 |
| Travel and Lodging | $6,116.48 |
| Consulting Fee | $4,425.00 |
| Education | $441.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $105,204.22 | 2020-2025 | Otezla, Otezla |
| Celgene Corporation | $16,137.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $6,745.30 | 2022-2025 | Sotyktu |
| Pfizer INC. | $4,432.50 | 2019-2025 | |
| Janssen Biotech, INC. | $1,427.25 | 2019-2025 | Tremfya |
| Genzyme Corporation | $1,354.13 | 2019-2025 | |
| Abbvie INC. | $1,281.52 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $749.60 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Incyte Corporation | $701.71 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $516.08 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $478.67 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $430.76 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $409.36 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $352.92 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $320.41 | 2019-2025 | Aklief, Epsolay, Twyneo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $302.28 | 2019-2025 | Klisyri |
| Prugen, INC. Pharmaceuticals | $298.87 | 2019-2020 | |
| Lilly USA, LLC | $247.60 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $243.52 | 2021-2022 | |
| Hill Dermaceuticals, INC. | $234.86 | 2025 | Tolak |
| Dermavant Sciences, INC. | $215.84 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $192.82 | 2019-2025 | |
| Dermira, INC. | $157.74 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $126.19 | 2019 | |
| Vyne Pharmaceuticals INC. | $126.11 | 2020-2021 | |
| Allergan, INC. | $44.83 | 2022 | |
| Janssen Scientific Affairs, LLC | $30.12 | 2019 | |
| Genentech USA, INC. | $28.20 | 2024 | Erivedge |
| Boston Scientific Corporation | $27.24 | 2023 | Wavewriter Alpha Prime 16 |
| Promius Pharma LLC | $25.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.33 | 2024 | Spevigo |
| Lundbeck LLC | $22.70 | 2024 | Rexulti |
| Aclaris Therapeutics, INC. | $19.80 | 2019 | |
| Mission Pharmacal Company | $18.36 | 2019 | |
| Journey Medical Corporation | $17.44 | 2023 | |
| Axsome Therapeutics, INC. | $14.45 | 2025 | Auvelity |
| Biofrontera INC. | $10.56 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bradshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.